Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | active not recruiting | Phase 3 | 298 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT00569127 | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | active not recruiting | Phase 3 | 427 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 |
| clinicaltrials |
| NCT03049189 | Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients(COMPETE) | active not recruiting | Phase 3 | 324 | ITM Solucin GmbHINDUSTRY | 14 | Aug 7, 2026 | clinicaltrials |
| NCT04919226 | Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE(COMPOSE) | active not recruiting | Phase 3 | 259 | ITM Solucin GmbHINDUSTRY | 10 | Sep 10, 2025 | clinicaltrials |
| NCT05459844 | A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs | active not recruiting | Phase 3 | 196 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
Data updated 5 days agoSource updated Sep 22, 2026source: clinicaltrials